Drugs / Diphenylcyclopropenone
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05020496 | Mar 2022 → Jun 2027 expected | skin disorder | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01978483 | Nov 2013 → Jun 2014 | drug allergy, immunodeficiency disease, type IV hypersensitivity disease | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01711684 | Oct 2012 → Jun 2015 | melanoma, metastatic neoplasm | Rockefeller University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03651752 | Apr → Sep 2024 | alopecia areata | University of Minnesota | Terminated | No outcome recorded Stop: Enrollment |
| Phase 41 trial | ||||||
| Phase 4 | NCT04775979 | Jan → Jul 2021 | vitiligo | Ain Shams University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diphenylcyclopropenone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01978483 ↗ |
| Known as | DPCP | “Diphenylcyclopropenone (DPCP) Ointment” NCT03651752 ↗1“Diphenylcyclopropenone (DPCP)” NCT05020496 ↗ |
| Route | Topical | “as a topical immunotherapeutic agent” NCT01711684 ↗ |